Could cause temporary or reversible harm; serious harm is unlikely.
Presence of Foreign Tablets/Capsules
| Brand name | BUPROPION HYDROCHLORIDE |
| Generic name | BUPROPION HYDROCHLORIDE |
| Active ingredient(s) | BUPROPION HYDROCHLORIDE |
| Distributed by / for | Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 |
| NDC | 16571-862-03 |
| Full product label | buPROPion Hydrochloride Extended-Release Tablets, USP (XL) 150mg, 30-count bottles, Rx Only, Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Manufactured by: Graviti Pharmaceuticals Pvt. Ltd. Telangana - 502307, INDIA, NDC 16571-862-03 |
| Recalling firm | Rising Pharma Holding, Inc. |
| Distribution | Nationwide within the United States |
| Quantity | 47,976 bottles |
| Recall initiated | 2023-12-29 |
| Report date | 2024-01-17 |
| Recall completed | — |
| Recall number | D-0222-2024 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | East Brunswick NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗